OCRELIZUMAB (OCREVUS) prior authorization at Florida Blue
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
The PA criteria you'll need to meet
Florida Blue reviews OCRELIZUMAB (OCREVUS) prior authorizations against its medical policy for CD20-directed Cytolytic Antibody [EPC]. The FDA-approved indication (2017) is INJECTABLE. Florida Blue-specific context: BCBS licensee for Florida (~5M members). Owned by GuideWell. Prime Therapeutics is the PBM (BCBS-aggregated PBM serving 19 BCBS plans). Florida OIR oversight. Largest ACA Marketplace participant in FL.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in CD20-directed Cytolytic Antibody [EPC]
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Florida Blue's medical policy URL referenced in the cover letter
Florida Blue's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Marketplace narrow-network denials (BlueCare, myBlue)
- Step therapy via Prime Therapeutics PBM
- Out-of-network reductions citing UCR
- Specialty drug prior auth
If the PA is denied
Florida Blue gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://providers.floridablue.com) with the same packet plus a peer-reviewed citation supporting OCRELIZUMAB (OCREVUS)for the patient's indication.
Contact Florida Blue
- Provider portal: https://providers.floridablue.com
Frequently asked questions
What documentation does Florida Blue need for OCRELIZUMAB (OCREVUS) prior auth?
Florida Blue's typical PA packet for OCRELIZUMAB (OCREVUS): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For CD20-directed Cytolytic Antibody [EPC], expect clinical-criteria documentation specific to this class.
What's the turnaround time at Florida Blue?
Standard OCRELIZUMAB (OCREVUS) PA decisions at Florida Blue: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Florida Blue most often reject OCRELIZUMAB (OCREVUS) for?
Across Florida Blue's book the common rejection patterns include: Marketplace narrow-network denials (BlueCare, myBlue); Step therapy via Prime Therapeutics PBM; Out-of-network reductions citing UCR. For OCRELIZUMAB (OCREVUS) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
How do I prep for a peer-to-peer with Florida Blue on OCRELIZUMAB (OCREVUS)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Generate the OCRELIZUMAB (OCREVUS) PA packet
Open ApprovalHelp — generate a OCRELIZUMAB (OCREVUS) prior-auth packet tailored to Florida Blue's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com